Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icn PharmaceuticalsfiledCriticalIcn Pharmaceuticals
Priority to ARP020103148priorityCriticalpatent/AR035301A1/en
Publication of AR035301A1publicationCriticalpatent/AR035301A1/en
Un compuesto nucleósido conforme a la fórmula (1) donde R1 es un grupo de enmascaramiento del grupo amino; R2 es H, un radical de aminoácido, -C(O)R o -P(O)(OR')2, donde R es alquilo C1-17, alquenilo o alquinilo, y R' es un grupo de enmascaramiento del grupo fosfato; R3 y R3' son, independientemente entre sí, H o acilo C1-18; y donde R1 y R2 no son hidrógeno al mismo tiempo. Uso de dicho compuesto para preparar una composición farmacéutica de utilidad en el tratamiento de una infección viral con virus HCV o HBV.A nucleoside compound according to formula (1) wherein R1 is a masking group of the amino group; R2 is H, an amino acid radical, -C (O) R or -P (O) (OR ') 2, where R is C1-17 alkyl, alkenyl or alkynyl, and R' is a phosphate group masking group ; R3 and R3 'are, independently of each other, H or C1-18 acyl; and where R1 and R2 are not hydrogen at the same time. Use of said compound to prepare a pharmaceutical composition useful in the treatment of a viral infection with HCV or HBV virus.